T cell avidity and tumor recognition: implications and therapeutic strategies

• Published in: Journal of translational medicine Vol. 3; no. 1; p. 35
• Main Authors: McKee, Mark D, Roszkowski, Jeffrey J, Nishimura, Michael I
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 20.09.2005; BioMed Central; BMC
• Subjects: Review
• ISSN: 1479-5876; 1479-5876
• DOI: 10.1186/1479-5876-3-35

In the last two decades, great advances have been made studying the immune response to human tumors. The identification of protein antigens from cancer cells and better techniques for eliciting antigen specific T cell responses in vitro and in vivo have led to improved understanding of tumor recognition by T cells. Yet, much remains to be learned about the intricate details of T cell-tumor cell interactions. Though the strength of interaction between T cell and target is thought to be a key factor influencing the T cell response, investigations of T cell avidity, T cell receptor (TCR) affinity for peptide-MHC complex, and the recognition of peptide on antigen presenting targets or tumor cells reveal complex relationships. Coincident with these investigations, therapeutic strategies have been developed to enhance tumor recognition using antigens with altered peptide structures and T cells modified by the introduction of new antigen binding receptor molecules. The profound effects of these strategies on T cell-tumor interactions and the clinical implications of these effects are of interest to both scientists and clinicians. In recent years, the focus of much of our work has been the avidity and effector characteristics of tumor reactive T cells. Here we review concepts and current results in the field, and the implications of therapeutic strategies using altered antigens and altered effector T cells.